GPP
Generalized Pustular Psoriasis (GPP) is a rare, lifelong skin disease, which may be life-threatening if left untreated.
Search
FDA Approves OFEV® (nintedanib) to Treat IPF | BI US
Read more about the FDA approval of Boehringer Ingelheim's OFEV, the first Kinase Inhibitor used to treat idiopathic pulmonary fibrosis (IPF).
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
Swine Vaccine Combo for Two Diseases | Boehringer Ingelheim US
Click here to read more on the launch of the Boehringer Ingelheim innovative vaccine combination, protecting US swine from two viruses in one shot.
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
Your Milestones Drive Ours
Learn more about the experiences of living with nonsmall cell lung cancer and cholangiocarcinoma as well as caring for a loved one during a cancer journey.
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
Tackling Health Disparities and Inequities for Women With Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care
Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
our-inflammatory-disease-research.pdf
Partnering-Infectious-Diseases.pdf
Patient-centric cardio-renal-metabolic disease research at Boehringer Ingelheim
Cardiovascular Disease in T2D
CV Disease in T2D Background
AH-Partnering-Cardiometabolic-Diseases.pdf
partnering-immunology-respiratory-diseases.pdf
AH-Partnering-CNS-Diseases.pdf
Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards
Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards
Collaboration with Mary Tyler Moore Vision Initiative
Boehringer Ingelheim joins forces with Mary Tyler Moore Vision Initiative to combat vision loss from diabetes
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction
Obesity
Obesity
Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders
Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders
Our Science Focus
Our Science Focus